United Kingdom · Question · Written question
UIN 73126
Obesity: Drugs
Introduced
29 August 2025
Last action
9 September 2025 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
9 September 2025
Summary
To ask the Secretary of State for Health and Social Care, what steps he has taken to ensure post-market surveillance of NHS-provided weight loss drugs to monitor their long-term effects in patients.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
29 August 2025
Written question
To ask the Secretary of State for Health and Social Care, what steps he has taken to ensure post-market surveillance of NHS-provided weight loss drugs to monitor their long-term effects in patients.
Source: Commons
9 September 2025
Answer
The newest obesity medicines, liraglutide, under various brand names, semaglutide, under the brand name Wegovy, and tirzepatide, under the brand name Mounjaro, have only been licensed and recommended for use for the treatment of obesity over the last few ...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-08-29/73126
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1829883
- uk · wq-1829883 · source updated 9 September 2025